Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
NASDAQ:HALO
Price:
44.71 USD
-1.5%
Market Closed
Updated:
May 18, 2024
Halozyme Therapeutics Inc
Research & Development
|
Halozyme Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Research & Development
-$77.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Halozyme Therapeutics Inc's Research & Development?
Research & Development
-77.4m
USD
-77.4m
USD
Based on the financial report for Mar 31, 2024, Halozyme Therapeutics Inc's Research & Development amounts to -77.4m USD.
What is Halozyme Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
2%
2%
Over the last year, the Research & Development growth was -6%. The average annual Research & Development growth rates for Halozyme Therapeutics Inc have been -33% over the past three years , 12% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
